You should do the test again.

https://www.journal-of-hepatology.eu/article/S0168-8278(16)00010-6/fulltext

Whatever the cause, the problem of hepatic decompensation during antiviral therapy calls for heightened awareness and careful monitoring of patients with cirrhosis who receive antiviral therapy for hepatitis C. The first appearance of features of decompensation should lead to rapid initiation of appropriate supportive care and early discontinuation of antiviral treatment. For the research community, an important priority is to establish objective criteria for hepatic decompensation to use in describing results and to standardize reporting rates across clinical trials. The episodes of acute decompensation also need to be better described clinically, particularly in the context of other adverse events, timing of viral clearance, serum enzyme changes and serial bilirubin, albumin, ammonia and lactate levels. These studies are of great priority because treatment of patients with advanced hepatitis C cannot be withheld because of concern for this complication.

What is your HCV genotype?
Do you have cirrhosis? What F-score do you have for your liver?

This is an emergency at least to take another urgent test and schedule an emergent consultation with a hepatologist to see if another test for hepatic decompensation or liver damage is available.

Greedfighter, it means intermediate is for factories, home compounding is not possible, unlike with some other drugs.
The quality of drug depends on quality control and chemical processes employed by both ingredient and pill manufacturer. Every factory is different, but both Bangladeshi manufacturers have been successful so far at ensuring the quality of the final product.

Gilead produces api in factories in many countries, the data is publicly available.

Hi!
I was gen 1b and the results are being updated in my signature. I’m 1m into treatment.
I read of several (>5) gen 3 people who were cured with sofosvel on hcv.ru Probably no difference btw the two generics (sofosvel and panovir – which I’m being cured with now).
Otherwise, check the trial results. On sof/vel and on pibrentasvir/glecaprevir.
As far as I see, there is no reason to defer treatment as many retreatment options are coming – and you never know what works.
If I were you I’d sof/vel. And if were unsuccessful, retreat with abbvie’s combination. However, read everything carefully. Individual experience does not count. Trial data is a bit more reliable.
There is few data and you can just read through and see what works for you.
Wish you best luck with your treatment.

Glecaprevir pibrentasvir will probably get FDA approval soon. https://news.abbvie.com/news/abbvie-submits-new-drug-application-to-us-fda-for-its-investigational-regimen-glecaprevirpibrentasvir-gp-for-treatment-all-major-genotypes-chronic-hepatitis-c.htm
Abbvie filed for FDA approval, days after Gilead. The timeframe is about 8 months.
This combination is even more potent than sof/vel/vox for retreatment, has a different resistance profile.
That said, sof/vel/vox does have 97% SVR for retreating many cases.
The more different drugs for retreatment – the better. Some failed combinations require retreatment with drugs having a different mechanism of action and resistance profile. And if one doesn’t work, it may be good to try chances with another one (although, there’s debate if one should wait for a year before retreatment, especially when one has a s282t rav).

I wonder who will be the first one to copycat it. The retreatment market is about 18 million people – and there are no good options on the market currently.

Gilead filed for FDA approval. The approval is expected in several months.
The market is about 18 million people.
http://www.gilead.com/news/press-releases/2016/12/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-the-investigational-single-tablet-regimen-sofosbuvirvelpatasvirvoxilaprevir
P.S. Likely to be approved either in July or October, 2017 depending on designation.

Thank you for information!
J. Eugene, RAVs matter mostly in those with fibrosis.
The study found that baseline RAVs significantly influence SVR in people with decompensated cirrhosis. Baseline RAVs do matter for non-cirhotic people, esp. for 3 patients (and slightly, for gen 1a). But for other genotypes (like 2,4,1b) they matter less. It’s not all black-and-white, of course, and baseline RAVs do have an influence for certain combinations of genotype and fibrosis level, but the statistics in the EMA report was for participants with decompensated cirhosis.

Many NS3 RAVs resulting from treatment generally disappear by themselves in about more than 1 year. Ns5b sofosbuvir-emergent RAVs – in about less than 1 year.
However, acquired NS5A RAVs persist, requiring retreatment with drugs having considerably different resistance profile/mechanism of action/high bareer to resistance.
Results from a small 3-year follow-up study (presented at AASLD 2016).

http://www.natap.org/2016/AASLD/AASLD_61.htm

There are drugs in development that target not the virus, but host proteins, and were shown to work in early trials. However, different direct acting antiviral drug combinations were also shown to be effective for retreatment in many cases.